1. Canada Stocks

  2. •

    Finance

  3. •

    Financial conglomerates
NeuroThera Labs Inc.

NeuroThera Labs Inc.

0.35
CAD
- -
- -
-0.01EPS
2021 Y
2022 Y
2023 Y
2024 Y
2024 Y
2025 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.01
- -
- -
- -
Basic EPS, GAAP
- -
-0.01
- -
- -
-0.01
- -
-0.02
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
-0.01
- -
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
0.01
0.01
0.02
- -
0.01
- -
0.01
Tangible Book Value per Share
0.01
0.01
0.01
0.02
- -
0.01
- -
0.01
Basic Weighted Avg Shares
16
18
57
58
202
58
215
36
Sales/Revenue/Turnover
- -
- -
- -
- -
1
- -
1
- -
Operating Margin (%)
- -
- -
- -
- -
-214.78
- -
-484.46
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
-3
- -
-4
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
-225.27
- -
-481.66
- -
Working Capital
- -
1
1
1
- -
1
- -
1
LT Debt
- -
- -
- -
- -
- -
- -
1
- -
Total Equity
- -
1
1
1
2
1
1
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-20.39
-5.78
-9.79
-353.5
-24.79
-1,068.27
-22.64

Capital Structure

USD

•

in mil. unless spec.
Jan'25
Apr'25
Jul'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
58
58
58
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Jan'25
Apr'25
Jul'25
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
5.28%
1.58%
Free Cash Flow
- -
920.87%
1,609.26%
Net Income, GAAP
- -
1,166.54%
2,239.42%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
-0.02

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Oz Adler
Sector
Finance
Industry
Financial conglomerates
Address
Vancouver Canada
Similar Companies
Strategy Inc (NASDAQ:MSTR)
BitMine Immersion Technologies, Inc. (NYSE:BMNR)
Strive, Inc. (NASDAQ:ASST)
Hyperliquid Strategies Inc (NASDAQ:PURR)
Stablecoin Development Corporation (AMEX:SDEV)
Jio Financial Services Limited (NSE:JIOFIN)
Business
NeuroThera Labs Inc. is a clinical-stage specialty pharmaceutical company focused on the research, development, and commercialization of proprietary therapeutic platforms for the treatment of central nervous system disorders. Headquartered in Vancouver, British Columbia, Canada, and originally incorporated in 2017, the company operates as a biopharmaceutical subsidiary of SciSparc Ltd. with research, clinical, and corporate activities spanning North America, Europe, and the Middle East. The company's core product and technology portfolio comprises proprietary cannabinoid-based combination pharmaceuticals and computational data technologies, including: SCI-110, an investigational oral formulation combining dronabinol (synthetic delta-9-tetrahydrocannabinol) and palmitoylethanolamide (PEA) evaluated for the treatment of Tourette syndrome and agitation in Alzheimer's disease; SCI-210, a dual-action drug candidate combining cannabidiol (CBD) and palmitoylethanolamide developed for autism spectrum disorder (ASD) and status epilepticus; proprietary N-acylethanolamine-based potentiator drug delivery formulations designed to increase safety and therapeutic efficacy while reducing adverse effects; and CliniQuantum, a quantum-enabled computational analytics platform utilizing hybrid quantum-classical simulation workflows and quantum Monte Carlo algorithms to optimize clinical trial design, biomarker discovery, and clinical dataset processing. In recent corporate and operational developments, the company completed a reverse takeover and corporate restructuring with Miza III Ventures Inc. to spin out SciSparc Ltd.'s clinical pharmaceutical assets and establish NeuroThera Labs Inc. as a publicly traded entity on the TSX Venture Exchange. Strategically expanding its analytical capabilities, the company acquired a controlling 54% majority interest in Israeli technology firm CliniQuantum Ltd. and validated an end-to-end hybrid quantum-classical computing workflow for real-world clinical trial data. NeuroThera also closed private placement equity financings raising gross proceeds of CAD 5.4 million with participation from parent entity SciSparc Ltd., progressed international multi-center Phase IIb clinical trials for SCI-110 across clinical sites in the United States, Germany, and Israel, and expanded its global intellectual property portfolio through patent grants in major jurisdictions, including Japan.